As new drugs targeting the CD200/CD200R interaction enter into clinical trials in humans, this work identifies this immune checkpoint as a potential target for patients with NSCLC and lays the groundwork for the development of a clinical companion diagnostic test. This evidence concerns the gene CD200R1 and non-small cell lung carcinoma.